From 11:00 pm to 12:00 pm EST ( 8:00 pm to 9:00 pm PST ) on January 6th, the website will be under maintenance. We are sorry for the inconvenience. Please arrange your schedule properly.
Ofatumumab is a fully humananti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL) .
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20+ non-Hodgkin lymphomas .
Tositumomab (Anti-HumanCD20 Recombinant Antibody) is a mouse-derived IgG2a monoclonal antibody, targeting to humanCD20. Tositumomab can deplete B cells. Tositumomab can be used for the research of cancer, such as lymphoma .
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
Anti-Monkey/HumanCD20 Antibody (2H7) is a mouse-derived IgG2b κ type antibody inhibitor, targeting to monkey/humanCD20. Anti-Monkey/HumanCD20 Antibody (2H7) specifically depletes B cells. Anti-Monkey/HumanCD20 Antibody (2H7) can be used for the researches of inflammation and metabolic disease, such as diabetes and experimental autoimmune encephalomyelitis .
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) .
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .
Anti-CD20 Antibody (mAb 1.5.3) is a fully human IgG1 anti-CD20 antibody. Anti-CD20 Antibody (mAb 1.5.3) evokes enhanced pro-apoptotic activity in vitro. Anti-CD20 Antibody (mAb 1.5.3) mediated both complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Anti-CD20 Antibody (mAb 1.5.3) demonstrates enhanced anti-tumor activity in various tumor xenograft models. Anti-CD20 Antibody (mAb 1.5.3) produces a superior B-cell depletion profile in lymph node organs and bone marrow in a primate pharmacodynamic model. Anti-CD20 Antibody (mAb 1.5.3) can be studied in research for B-cell maglignancies .
BVX20 is a human monoclonal antibody that binds to CD20. BVX20 can kill B-cells through recruiting the immune system. BVX20 can be studied in research for relapsed or chemotherapy-resistant follicular B-cell NHL and CD20-positive diffuse large B-cell NHL .
PSB102 is a humanized Fc-enhanced IgG1 monoclonal antibody directed against the human B-cell-specific cell surface antigen and tumor-associated antigen CD20 .
NAV006 is an anti-CD20 antibody variant of Rituximab (HY-P9913) with a Kd of 30.5 nM to CD20. NAV006 exhibits reduced interaction with CA125 and demonstrates enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity. NAV006 displays antitumor activity against lymphoma and can be used in research on non-Hodgkin lymphoma .
PRO131921 is a humanized IgG1 anti-CD20 antibody, with antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities. PRO131921 acts as an anti-tumor agent. PRO131921 can be used for the research of indolent non-Hodgkin lymphoma and relapsed and refractory indolent lymphoma .
Ofatumumab is a fully humananti-CD20 monoclonal antibody that induces antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) in CD20-expressing B lymphocytes. Ofatumumab has strong lytic activity against CD20-positive B lymphocytes and eliminates CD20-positive tumor cells through ADCC and CDC. Ofatumumab is particularly effective against drug-resistant cells with low CD20 expression and can be applied to the research of chronic lymphocytic leukemia (CLL) .
Utomilumab (PF 05082566) is a fully human IgG2 agonist monoclonal antibody that selectively binds to 4-1BB/CD137. Utomilumab can be used in the research of tumors such as follicular and other CD20+ non-Hodgkin lymphomas .
Tositumomab (Anti-HumanCD20 Recombinant Antibody) is a mouse-derived IgG2a monoclonal antibody, targeting to humanCD20. Tositumomab can deplete B cells. Tositumomab can be used for the research of cancer, such as lymphoma .
Odronextamab is a stable humanized IgG4 CD20 × CD3 bispecific antibody that binds to CD3 on T cells and CD20 on B cells, triggering anti-tumor activity. Odronextamab is expected to be used in oncology research .
Inbakicept is a dimeric human IL-15 receptor alpha (IL-15 Ra) sushi domain/human IgG1 Fc fusion protein and is an IL-15 superagonist complex. Inbakicept is able to form complex N-803 (Nogapendekin alfa inbakicept) with the IL-15 antibody Nogapendekin alfa in a 1:2 ratio. N-803 mimics the function of IL-15 and amplifies anti-CD20 mAb-mediated NK cell responses and antibody-dependent cellular cytotoxicity (ADCC). N-803 also increases degranulation and IFNγ production in cells .
Plamotamab (XmAb-13676) is a human bispecific antibody (bsAb) that binds CD3 and CD20. Plamotamab recruits cytotoxic T cells to kill CD20+ expressing tumor cells. Plamotamab induces a mild hematologic reaction (MR), and results in tumor regression in vivo .
Anti-Monkey/HumanCD20 Antibody (2H7) is a mouse-derived IgG2b κ type antibody inhibitor, targeting to monkey/humanCD20. Anti-Monkey/HumanCD20 Antibody (2H7) specifically depletes B cells. Anti-Monkey/HumanCD20 Antibody (2H7) can be used for the researches of inflammation and metabolic disease, such as diabetes and experimental autoimmune encephalomyelitis .
Ripertamab (SCT400) is a recombinant, human-mouse chimeric anti-CD20 IgG1κ mAb. Ripertamab can be used for the research of hematological malignancies, including non-Hodgkin’s lymphoma (NHL) .
BI-1206 is a recombinant and antagonistic human monoclonal antibody targeting FcγRIIB (CD32B). BI-1206 can block CD20 internalization induced by Rituximab (HY-P9913) itself or combined with others including Ibrutinib (HY-10997), Venetoclax (HY-15531), and CHOP. BI-1206 can enhance or recover the activity of Rituximab or other anti-CD20 monoclonal antibodies. BI-1206 has cytolytic activity against malignant B cells. BI-1206 can be studied for cancer research such as mantle cell lymphoma (MCL) .
Ibritumomab is a mouse antibody expressed in CHO, targeting CD20/MS4A1. Ibritumomab is equipped with a huIgG1 heavy chain and a huκ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for Ibritumomab can refer to Human IgG1 kappa, Isotype Control (HY-P99001).
Anti-CD20 Antibody (mAb 1.5.3) is a fully human IgG1 anti-CD20 antibody. Anti-CD20 Antibody (mAb 1.5.3) evokes enhanced pro-apoptotic activity in vitro. Anti-CD20 Antibody (mAb 1.5.3) mediated both complement-dependent cytotoxicity and antibody-dependent cellular cytotoxicity. Anti-CD20 Antibody (mAb 1.5.3) demonstrates enhanced anti-tumor activity in various tumor xenograft models. Anti-CD20 Antibody (mAb 1.5.3) produces a superior B-cell depletion profile in lymph node organs and bone marrow in a primate pharmacodynamic model. Anti-CD20 Antibody (mAb 1.5.3) can be studied in research for B-cell maglignancies .
Anti-CD20 Antibody is a humanized antibody expressed in CHO that targets CD20/MS4A1. The Anti-CD20 Antibody is composed of huIgG1 heavy chain and huκ light chain, with a predicted molecular weight (MW) of 150 kDa. The isotype control for Anti-CD20 Antibody can refer to Human IgG2 kappa, Isotype Control (HY-P99002).
BVX20 is a human monoclonal antibody that binds to CD20. BVX20 can kill B-cells through recruiting the immune system. BVX20 can be studied in research for relapsed or chemotherapy-resistant follicular B-cell NHL and CD20-positive diffuse large B-cell NHL .
PSB102 is a humanized Fc-enhanced IgG1 monoclonal antibody directed against the human B-cell-specific cell surface antigen and tumor-associated antigen CD20 .
NAV006 is an anti-CD20 antibody variant of Rituximab (HY-P9913) with a Kd of 30.5 nM to CD20. NAV006 exhibits reduced interaction with CA125 and demonstrates enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) activity. NAV006 displays antitumor activity against lymphoma and can be used in research on non-Hodgkin lymphoma .
PRO131921 is a humanized IgG1 anti-CD20 antibody, with antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities. PRO131921 acts as an anti-tumor agent. PRO131921 can be used for the research of indolent non-Hodgkin lymphoma and relapsed and refractory indolent lymphoma .
CD20/MS4A1 Protein-VLP, Human (HEK293) is recommended for animal immunization, ELISA, PK assay. If VLP control is required, it is recommended HY-P702775. May have binding signals with Anti-His antibodies.
CD20/MS4A1 protein is a B lymphocyte membrane protein that plays a crucial regulatory role in cellular calcium influx, which is essential for the development, differentiation and activation of B lymphocytes. As part of a store-operated calcium (SOC) channel, it promotes calcium influx upon B cell receptor/BCR activation. CD20/MS4A1 Protein, Human (HEK293, His, Nanodisc) is the recombinant human-derived CD20/MS4A1 protein, expressed by HEK293, with C-His labeled tag.
CD20/MS4A1 protein is a B lymphocyte membrane protein that plays a crucial regulatory role in cellular calcium influx, which is essential for the development, differentiation and activation of B lymphocytes. As part of a store-operated calcium (SOC) channel, it promotes calcium influx upon B cell receptor/BCR activation. FITC-Labeled CD20/MS4A1 Protein, Human (HEK293, His, Nanodisc) is the recombinant human-derived FITC-Labeled CD20/MS4A1 protein, expressed by HEK293, with C-His labeled tag.
CD20/MS4A1 protein is a B lymphocyte membrane protein that plays a crucial regulatory role in cellular calcium influx, which is essential for the development, differentiation and activation of B lymphocytes. As part of a store-operated calcium (SOC) channel, it promotes calcium influx upon B cell receptor/BCR activation. CD20/MS4A1 Protein, Human (Trx-His) is the recombinant human-derived CD20/MS4A1 protein, expressed by E. coli , with N-Trx, N-6*His labeled tag.
CD20/MS4A1 protein is a B lymphocyte membrane protein that plays a crucial regulatory role in cellular calcium influx, which is essential for the development, differentiation and activation of B lymphocytes. As part of a store-operated calcium (SOC) channel, it promotes calcium influx upon B cell receptor/BCR activation. CD20/MS4A1 Protein, Human (His-Avi) is the recombinant human-derived CD20/MS4A1 protein, expressed by E. coli , with C-Avi, C-His labeled tag.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website.
Privacy and Cookie Policy
